The role of death receptors in neural injury

Frontiers in Bioscience

Volumn 14, Issue 2, 2009, Pages 583-595

  Lorz, Corina ^a,b   Mehmet, Huseyin ^a,c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Molecular Oncology Unit   (Spain)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Apoptosis; CNS; Death receptors; Injury; Review

Indexed keywords

DEATH RECEPTOR;

APOPTOSIS; BRAIN DISEASE; BRAIN INJURY; HUMAN; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

APOPTOSIS; BRAIN DISEASES; BRAIN INJURIES; HUMANS; RECEPTORS, DEATH DOMAIN;

EID: 63849306507     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3265     Document Type: Review

References (136)

1. K. F. Ferri and G. Kroemer: Organelle-specific initiation of cell death pathways. Nat Cell Biol, 3(11), E255-63(2001)
2. X. Luo, I. Budihardjo, H. Zou, C. Slaughter and X. Wang: Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell, 94(4), 481-90(1998) (Pubitemid 28391864)
3. L. Lossi, S. Mioletti and A. Merighi: Synapseindependent and synapse-dependent apoptosis of cerebellar granule cells in postnatal rabbits occur at two subsequent but partly overlapping developmental stages. Neuroscience, 112(3), 509-23(2002) (Pubitemid 34634146)
4. D. Thomaidou, M. C. Mione, J. F. Cavanagh and J. G. Parnavelas: Apoptosis and its relation to the cell cycle in the developing cerebral cortex. J Neurosci, 17(3), 1075-85(1997) (Pubitemid 27043966)
5. L. Lossi and A. Merighi: In vivo cellular and molecular mechanisms of neuronal apoptosis in the mammalian CNS. Prog Neurobiol, 69, 287-312(2003) (Pubitemid 36645051)
6. M. Vila and S. Przedborski: Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci, 4, 365-375(2003) (Pubitemid 37280175)
7. J. H. Su, A. J. Anderson, B. J. Cummings and C. W. Cotman: Immunohistochemical evidence for apoptosis in Alzheimer's disease. Neuroreport, 5, 2529-2533(1994)
8. L. A. Selznick, D. M. Holtzman, B. H. Han, M. Gokden, A. N. Srinivasan, E. M. J. Johnson and K. A. Roth: In situ immunodetection of neuronal caspase-3 activation in Alzheimer disease. J Neuropathol Exp Neurol, 58, 1020-1026(1999) (Pubitemid 29441930)
9. T. T. Rohn, E. Head, W. H. Nesse, C. W. Cotman and D. H. Cribbs: Activation of caspase-8 in the Alzheimer's disease brain. Neurobiol Dis. 8:, 8, 1006-1016(2001) (Pubitemid 34017094)
10. D. T. Loo, A. Copani, C. J. Pike, E. R. Whittemore, A. J. Walencewicz and C. W. Cotman: Apoptosis is induced by beta-amyloid in cultured central nervous system neurons. Proc Natl Acad Sci USA, 90, 7951-7955(1993) (Pubitemid 23260832)
11. R. A. Rissman, W. W. Poon, M. Blurton-Jones, S. Oddo, R. Torp, M. P. Vitek, F. M. LaFerla, T. T. Rohn and C. W. Cotman: Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest, 114(1), 121-30(2004) (Pubitemid 39071651)
12. D. C. Lu, S. Rabizadeh, S. Chandra, R. F. Shayya, L. M. Ellerby, X. Ye, G. S. Salvesen, E. H. Koo and D. E. Bredesen: A second cytotoxic proteolytic peptide derived from amyloid beta-protein precursor. Nat Med 6, 397-404(2000) (Pubitemid 30208156)
13. E. Brouillet, A. Trembleau, D. Galanaud, M. Volovitch, C. Bouillot, C. Valenza, A. Prochiantz and B. Allinquant: The amyloid precursor protein interacts with Go heterotrimeric protein within a cell compartment specialized in signal transduction. J Neurosci, 19(5), 1717-27(1999) (Pubitemid 29094190)
14. R. L. Neve and D. L. McPhie: Dysfunction of amyloid precursor protein signaling in neurons leads to DNA synthesis and apoptosis. Biochim Biophys Acta, 1772(4), 430-7(2007) (Pubitemid 46400381)
15. H. Mochizuki, K. Goto, H. Mori and Y. Mizuno: Histochemical detection of apoptosis in Parkinson's disease. J Neurol Sci, 137, 120-123(1996) (Pubitemid 26172041)
16. P. Anglade, S. Vyas, F. Javoy-Agid, M. T. Herrero, P. P. Michel, J. Marquez, A. Mouatt-Prigent, M. Ruberg, E. C. Hirsch and Y. Agid: Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol, 12(1), 25-31(1997) (Pubitemid 27106916)
17. N. A. Tatton, A. Maclean-Fraser, W. G. Tatton, D. P. Perl and C. W. Olanow: A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease. Ann Neurol, 44, S142-148 (1998) (Pubitemid 28423841)
18. A. Hartmann, S. Hunot, P. P. Michel, M. P. Muriel, S. Vyas, B. A. Faucheux, A. Mouatt-Prigent, H. Turmel, A. Srinivasan, M. Ruberg, G. I. Evan, Y. Agid and E. C. Hirsch: Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci U S A, 97(6), 2875-80(2000) (Pubitemid 30159265)
19. A. Hartmann, J. D. Troadec, S. Hunot, K. Kikly, B. A. Faucheux, A. Mouatt-Prigent, M. Ruberg, Y. Agid and E. C. Hirsch: Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis. J Neurosci, 21(7), 2247-55(2001) (Pubitemid 32240523)
20. V. Viswanath, Y. Wu, R. Boonplueang, S. Chen, F. F. Stevenson, F. Yantiri, L. Yang, M. F. Beal and J. K. Andersen: Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced Parkinson's disease. J Neurosci, 21, 9519-9528(2001) (Pubitemid 34184040)
21. E. M. Frohman, M. K. Racke and C. S. Raine: Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med, 354(9), 942-55(2006)
22. G. Wolswijk: Oligodendrocyte survival, loss and birth in lesions of chronic-stage multiple sclerosis. Brain 123, 123, 105-115(2000) (Pubitemid 30037973)
23. B. Bonetti and C. S. Raine: Multiple sclerosis: oligodendrocytes display cell death-related molecules in situ but do not undergo apoptosis. Ann Neurol, 42, 74-84(1997) (Pubitemid 27304783)
24. P. Dowling, W. Husar, J. Menonna, H. Donnenfeld, S. Cook and M. Sidhu: Cell death and birth in multiple sclerosis brain. J Neurol Sci, 149, 1-11(1997) (Pubitemid 27196374)
25. T. Sairanen, M. L. Karjalainen-Lindsberg, A. Paetau, P. Ijas and P. J. Lindsberg: Apoptosis dominant in the periinfarct area of human ischaemic stroke - a possible target of antiapoptotic treatments. Brain, 129(Pt 1), 189-99(2006) (Pubitemid 43063770)
26. H. Nawashiro, D. Martin and J. M. Hallenbeck: Neuroprotective effects of TNF binding protein in focal cerebral ischemia. Brain Res, 778, 265-271(1997) (Pubitemid 28037406)
27. S. Love, R. Barber, A. Srinivasan and G. K. Wilcock: Activation of caspase-3 in permanent and transient brain ischaemia in man. Neuroreport, 11, 2495-2499(2000) (Pubitemid 30622296)
28. C. Wiessner, D. Sauer, D. Alaimo and P. R. Allegrini: Protective effect of a caspase inhibitor in models for cerebral ischemia in vitro and in vivo. Cell Mol Biol, 46, 53-62(2000)
29. M. Rabuffetti, C. Sciorati, G. Tarozzo, E. Clementi, A. A. Manfredi and M. Beltramo: Inhibition of caspase-1-like activity by Ac-Tyr-Val-Ala-Asp- chloromethyl ketone induces long-lasting neuroprotection in cerebral ischemia through apoptosis reduction and decrease of proinflammatory cytokines. J Neurosci, 20, 4398-4404(2000) (Pubitemid 30396604)
30. S. Renolleau, S. Fau, C. Goyenvalle, L. M. Joly, D. Chauvier, E. Jacotot, J. Mariani and C. Charriaut-Marlangue: Specific caspase inhibitor Q-VD-OPh prevents neonatal stroke in P7 rat: a role for gender. J Neurochem, 100(4), 1062-71(2007) (Pubitemid 46213929)
31. D. L. Taylor, A. Edwards and H. Mehmet: Oxidative metabolism, apoptosis and perinatal brain injury. Brain Pathol, 9, 93-117(1999) (Pubitemid 29056522)
32. C. Zhu, X. Wang, X. Cheng, L. Qiu, F. Xu, G. Simbruner and K. Blomgren: Post-ischemic hypothermiainduced tissue protection and diminished apoptosis after neonatal cerebral hypoxia-ischemia. Brain Res, 996, 67-75(2004) (Pubitemid 37510295)
33. P. D. Gluckman, J. S. Wyatt, D. Azzopardi, R. Ballard, A. D. Edwards, D. M. Ferriero, R. A. Polin, C. M. Robertson, M. Thoresen, A. Whitelaw and A. J. Gunn: Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial. Lancet, 365(9460), 663-70(2005) (Pubitemid 40260887)
34. J. S. Wyatt, P. D. Gluckman, P. Y. Liu, D. Azzopardi, R. Ballard, A. D. Edwards, D. M. Ferriero, R. A. Polin, C. M. Robertson, M. Thoresen, A. Whitelaw and A. J. Gunn: Determinants of outcomes after head cooling for neonatal encephalopathy. Pediatrics, 119(5), 912-21(2007) (Pubitemid 46715661)
35. A. Ashkenazi and V. Dixit: Death receptors: signaling and modulation. Science, 281, 1305-1308(1998) (Pubitemid 28406815)
36. V. Baud and M. Karin: Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol, 11, 372-377(2001) (Pubitemid 32900529)
37. R. M. Locksley, N. Killeen and M. J. Lenardo: The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell, 104, 487-501(2001) (Pubitemid 32201945)
38. A. Thorburn: Death receptor-induced cell killing. Cell Signal, 16, 139-144(2004) (Pubitemid 37431163)
39. N. Holler, R. Zaru, O. Micheau, M. Thome, A. Attinger, S. Valitutti, J. L. Bodmer, P. Schneider, B. Seed and J. Tschopp: Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol, 1(6), 489-95(2000)
40. R. Watanabe-Fukunaga, C. I. Brannan, N. G. Copeland, N. Jenkins and S. Nagata: Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature, 356, 314-317(1992)
41. T. Takahashi, M. Tanaka, C. I. Brannan, N. Jenkins, N. Copeland, T. Suda and S. Nagata: Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell, 76, 969-976(1994) (Pubitemid 24106378)
42. M. Adachi, S. Suematsu, T. Kondo, J. Ogasawara, T. Tanaka, N. Yoshida and S. Nagata: Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat Genet, 11, 294-300(1995)
43. C. M. Vogelweid, G. C. Johnson, C. L. Besch-Williford, J. Basler and S. E. Walker: Inflammatory central nervous system disease in lupus-prone MRL/lpr mice: comparative histologic and immunohistochemical findings. J Neuroimmunol, 35, 89-99(1991)
44. B. Sakic, B. Kolb, I. Q. Whishaw, G. Gorny, H. Szechtman and J. A. Denburg: Immunosuppression prevents neuronal atrophy in lupus-prone mice: evidence for brain damage induced by autoimmune disease? J Neuroimmunol, 111, 93-101(2000)
45. A. D. Kovac, J. Grammig, J. Mahlo, B. Steiner, K. Roth, R. Nitsch and I. Bechmann: Comparison of neuronal density and subfield sizes in the hippocampus of CD95L-deficient (gld), CD95-deficient (lpr) and nondeficient mice. Eur J Neurosci, 16, 159-163(2002) (Pubitemid 35463608)
46. K. Kuida, T. S. Zheng, S. Na, C. Y. Kuan, D. Yang, H. Karasuyama, P. Rakic and R. A. Flavell: Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. Nature, 384, 368-372(1996) (Pubitemid 26408520)
47. K. Kuida, T. F. Haydar, C. Y. Kuan, Y. Gu, C. Taya, H. Karasuyama, M. S. Su, P. Rakic and R. A. Flavell: Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell, 94, 325-337(1998) (Pubitemid 28376077)
48. T. S. Griffith, T. Brunner, S. M. Fletcher, D. R. Green and T. A. Ferguson: Fas ligand-induced apoptosis as a mechanism of immune privilege. Science, 270, 1189-1192(1995)
49. J. S. Hunt, D. Vassmer, T. A. Ferguson and L. Miller: Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus. J Immunol, 158, 4122-4128(1997) (Pubitemid 127483910)
50. D. Bellgrau, D. Gold, H. Selawry, J. Moore, A. Franzusoff and R. C. Duke: A role for CD95 ligand in preventing graft rejection. Nature, 377, 630-632(1995)
51. K. Wosik, K. Biernacki, M. P. Khouzam and A. Prat: Death receptor expression and function at the human blood brain barrier. J Neurol Sci, 259(1-2), 53-60(2007) (Pubitemid 47031203)
52. S. D. D'Souza, B. Bonetti, V. Balasingam, N. R. Cashman, P. A. Barker, A. B. Troutt, C. S. Raine and J. P. Antel: Multiple sclerosis: Fas signaling in oligodendrocyte cell death. J Exp Med 184, 2361-2370(1996) (Pubitemid 27023735)
53. P. Dowling, G. Shang, S. Raval, J. Menonna, S. Cook and W. Husar: Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. J Exp Med, 184, 1513-1518(1996) (Pubitemid 26354706)
54. E. Ciusani, S. Frigerio, M. Gelati, E. Corsini, A. Dufour, A. Nespolo, L. La Mantia, C. Milanese, G. Massa and A. Salmaggi: Soluble Fas (Apo-1) levels in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 82, 5-12(1998) (Pubitemid 28129330)
55. H. Waldner, R. A. Sobel, E. Howard and V. K. Kuchroo: Fas-and FasL-deficient mice are resistant to induction of autoimmune encephalomyelitis. J Immunol, 159(7), 3100-3(1997) (Pubitemid 127482064)
56. Y. Okuda, S. Sakoda, H. Fujimura, S. Nagata, T. Yanagihara and C. C. Bernard: Intrathecal administration of neutralizing antibody against Fas ligand suppresses the progression of experimental autoimmune encephalomyelitis. Biochem Biophys Res Commun, 275(1), 164-8(2000) (Pubitemid 30663646)
57. B. Zhu, L. Luo, Y. Chen, D. W. Paty and M. S. Cynader: Intrathecal Fas ligand infusion strengthens immunoprivilege of central nervous system and suppresses experimental autoimmune encephalomyelitis. J Immunol, 169(3), 1561-9(2002) (Pubitemid 34809204)
58. Y. Okuda, B. R. Apatoff and D. N. Posnett: Apoptosis of T cells in peripheral blood and cerebrospinal fluid is associated with disease activity of multiple sclerosis. J Neuroimmunol, 171(1-2), 163-70(2006) (Pubitemid 41832287)
59. N. Hovelmeyer, Z. Hao, K. Kranidioti, G. Kassiotis, T. Buch, F. Frommer, L. von Hoch, D. Kramer, L. Minichiello, G. Kollias, H. Lassmann and A. Waisman: Apoptosis of oligodendrocytes via Fas and TNF-R1 is a key event in the induction of experimental autoimmune encephalomyelitis. J Immunol, 175(9), 5875-84(2005) (Pubitemid 41508072)
60. W. J. Streit: Microglia and Alzheimer's disease pathogenesis. J Neurosci Res 77, 1-8(2004) (Pubitemid 38850050)
61. J. H. Su, A. J. Anderson, D. H. Cribbs, C. Tu, L. Tong, P. Kesslack and C. W. Cotman: Fas and Fas ligand are associated with neuritic degeneration in the AD brain and participate in beta-amyloid-induced neuronal death. Neurobiol Dis 12, 182-193(2003) (Pubitemid 36542976)
62. M. Martinez, E. Fernandez-Vivancos, A. Frank, M. De la Fuente and A. Hernanz: Increased cerebrospinal fluid fas (Apo-1) levels in Alzheimer's disease. Relationship with IL-6 concentrations. Brain Res, 869(1-2), 216-9(2000) (Pubitemid 30345793)
63. S. M. de la Monte, Y. K. Sohn and J. R. Wands: Correlates of p53-and Fas (CD95)-mediated apoptosis in Alzheimer's disease. J Neurol Sci 152, 73-83(1997) (Pubitemid 27469712)
64. Y. Morishima, Y. Gotoh, J. Zieg, T. Barrett, H. Takano, R. A. Flavell, R. J. Davis, Y. Shirasaki and M. E. Greenberg: Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun. N-terminal kinase pathway and the induction of Fas ligand. J Neurosci, 21, 7551-7560(2001) (Pubitemid 32904954)
65. D. W. Ethell, R. Kinloch and D. R. Green: Metalloproteinase shedding of Fas ligand regulates betaamyloid neurotoxicity. Curr Biol 12, 1595-1600(2002)
66. M. Tanaka, T. Itai, M. Adachi and S. Nagata: Downregulation of Fas ligand by shedding. Nat Med 4, 31-36(1998) (Pubitemid 28133076)
67. F. Sabri, A. De Milito, R. Pirskanen, I. Elovaara, L. Hagberg, P. Cinque, R. Price and F. Chiodi: Elevated levels of soluble Fas and Fas ligand in cerebrospinal fluid of patients with AIDS dementia complex. J Neuroimmunol, 114(1-2), 197-206(2001) (Pubitemid 32184742)
68. A. Towfighi, R. L. Skolasky, C. St Hillaire, K. Conant and J. C. McArthur: CSF soluble Fas correlates with the severity of HIV-associated dementia. Neurology, 62(4), 654-6(2004) (Pubitemid 38252816)
69. A. Ghorpade, S. Holter, K. Borgmann, R. Persidsky and L. Wu: HIV-1 and IL-1 beta regulate Fas ligand expression in human astrocytes through the NF-kappa B pathway. J Neuroimmunol, 141, 141-149(2003) (Pubitemid 37289007)
70. M. Deshpande, J. Zheng, K. Borgmann, R. Persidsky, L. Wu, C. Schellpeper and A. Ghorpade: Role of activated astrocytes in neuronal damage: potential links to HIV-1-associated dementia. Neurotox Res, 7(3), 183-92(2005)
71. U. Felderhoff-Mueser, D. L. Taylor, K. Greenwood, M. Kozma, D. Stibenz, U. C. Joashi, A. D. Edwards and H. Mehmet Fas/CD95/APO-1 can function as a death receptor for neuronal cells in vitro and in vivo and is up regulated following cerebral hypoxic-ischemic injury to the developing rat brain. Brain Pathol 10, 17-29(2000) (Pubitemid 30056390)
72. A. Martin-Villalba, I. Herr, I. Jeremias, M. Hahne, R. Brandt, J. Vogel, J. Schenkel, T. Herdegen and K. M. Debatin: CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons. J Neurosci 19, 3809-3817(1999) (Pubitemid 29222257)
73. H. Mehmet: Stroke treatment enters the Fas lane. Cell Death Differ 8, 659-661(2001) (Pubitemid 32685162)
74. A. Martin-Villalba, M. Hahne, S. Kleber, J. Vogel, W. Falk, J. Schenkel and P. H. Krammer: Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke. Cell Death Differ 8, 679-686(2001) (Pubitemid 32685165)
75. D. Demjen, S. Klussmann, S. Kleber, C. Zuliani, B. Stieltjes, C. Metzger, U. A. Hirt, H. Walczak, W. Falk, M. Essig, L. Edler, P. H. Krammer and A. Martin-Villalba: Neutralization of CD95 ligand promotes regeneration and functional recovery after spinal cord injury. Nat Med, 10(4), 389-95(2004) (Pubitemid 38508517)
76. O. Micheau and J. Tschopp: Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell, 114(2), 181-90(2003) (Pubitemid 36936912)
77. K. Selmaj, C. S. Raine, B. Cannella and C. F. Brosnan: Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest, 87(3), 949-54(1991)
78. C. S. Raine, B. Bonetti and B. Cannella: Multiple sclerosis: expression of molecules of the tumor necrosis factor ligand and receptor families in relationship to the demyelinated plaque. Rev Neurol (Paris) 154, 577-585(1998) (Pubitemid 28467174)
79. L. Probert, K. Akassoglou, M. Pasparakis, G. Kontogeorgos and G. Kollias: Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. Proc Natl Acad Sci USA, 92, 11294-11298(1995)
80. L. Probert, K. Akassoglou, G. Kassiotis, M. Pasparakis, L. Alexopoulou and G. Kollias: TNF-alpha transgenic and knockout models of CNS inflammation and degeneration. J Neuroimmunol, 72, 137-141(1997) (Pubitemid 27063586)
81. K. Akassoglou, J. Bauer, G. Kassiotis, M. Pasparakis, H. Lassmann, G. Kollias and L. Probert: Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice: models for multiple sclerosis with primary oligodendrogliopathy. Am J Pathol (153), 801-813 (1998) (Pubitemid 28419033)
82. G. Kassiotis and G. Kollias: Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J Exp Med, 193, 427-434(2001) (Pubitemid 32524474)
83. B. W. van Oosten, F. Barkhof, L. Truyen, J. B. Boringa, F. W. Bertelsmann, B. M. von Blomberg, J. N. Woody, H. P. Hartung and C. H. Polman: Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology, 47, 1531-1534(1996) (Pubitemid 26422549)
84. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology, 53(3), 457-65(1999)
85. R. Gold, R. A. Linker and A. Chan: Termination of inflammation in the nervous system. Rev Neurol (Paris), 163(6-7), 672-6(2007) (Pubitemid 47015568)
86. K. Akassoglou, E. Douni, J. Bauer, H. Lassmann, G. Kollias and L. Probert: Exclusive tumor necrosis factor (TNF) signaling by the p75TNF receptor triggers inflammatory ischemia in the CNS of transgenic mice. Proc Natl Acad Sci USA, 100, 709-714(2003) (Pubitemid 36126117)
87. H. P. Eugster, K. Frei, R. Bachmann, H. Bluethmann, H. Lassmann and A. Fontana: Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1. Eur J Immunol, 29, 626-632(1999) (Pubitemid 29078524)
88. G. Kollias and D. Kontoyiannis: Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments. Cytokine Growth Factor Rev, 13, 315-321(2002)
89. T. Liu, R. K. Clark, P. C. McDonnell, P. R. Young, R. F. White, F. C. Barone and G. Z. Feuerstein: Tumor necrosis factor-alpha expression in ischemic neurons. Stroke, 25, 1481-1488(1994) (Pubitemid 24198599)
90. M. Buttini, K. Appel, A. Sauter, P. J. Gebicke-Haerter and H. W. Boddeke: Expression of tumor necrosis factor alpha after focal cerebral ischaemia in the rat. Neuroscience, 71, 1-16(1996) (Pubitemid 26041886)
91. K. Saito, K. Suyama, K. Nishida, Y. Sei and A. S. Basile: Early increases in TNF-alpha, IL-6 and IL-1 beta levels following transient cerebral ischemia in gerbil brain. Neurosci Lett, 206, 149-152(1996)
92. X. Wang, G. Z. Feuerstein, L. Xu, H. Wang, W. A. Schumacher, M. L. Ogletree, R. Taub, J. J. Duan, C. P. Decicco and R. Q. Liu: Inhibition of tumor necrosis factoralpha-converting enzyme by a selective antagonist protects brain from focal ischemic injury in rats. Mol Pharmacol, 65, 890-896(2004) (Pubitemid 38420494)
93. A. J. Bruce, W. Boling, M. S. Kindy, J. Peschon, P. J. Kraemer, M. K. Carpenter, F. W. Holtsberg and M. P. Mattson: Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat Med 2, 788-794(1996) (Pubitemid 26225095)
94. H. Nawashiro, K. Tasaki, C. A. Ruetzler and J. M. Hallenbeck: TNF-alpha pretreatment induces protective effects against focal cerebral ischemia in mice. J Cereb Blood Flow Metab 17, 4834-90(1997)
95. H. L. Rosenzweig, M. Minami, N. S. Lessov, S. C. Coste, S. L. Stevens, D. C. Henshall, R. Meller, R. P. Simon and M. P. Stenzel-Poore: Endotoxin preconditioning protects against the cytotoxic effects of TNFalpha after stroke: a novel role for TNFalpha in LPS-ischemic tolerance. J Cereb Blood Flow Metab (2007)
96. J. Castillo, M. A. Moro, M. Blanco, R. Leira, J. Serena, I. Lizasoain and A. Davalos: The release of tumor necrosis factor-alpha is associated with ischemic tolerance in human stroke. Ann Neurol 54, 811-819(2003) (Pubitemid 37498964)
97. E. Taoufik, S. Valable, G. J. Muller, M. L. Roberts, D. Divoux, A. Tinel, A. Voulgari-Kokota, V. Tseveleki, F. Altruda, H. Lassmann, E. Petit and L. Probert: FLIP (L) protects neurons against in vivo ischemia and in vitro glucose deprivation-induced cell death. J Neurosci, 27(25), 6633-46(2007) (Pubitemid 46983433)
98. R. Klein, V. Nanduri, S. A. Jing, F. Lamballe, P. Tapley, S. Bryant, C. Cordon-Cardo, K. R. Jones, L. F. Reichardt and M. Barbacid: The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. Cell 66, 395-403(1991) (Pubitemid 121001376)
99. R. Klein, S. Q. Jing, V. Nanduri, E. O'Rourke and M. Barbacid: The trk proto-oncogene encodes a receptor for nerve growth factor. Cell, 65(1), 189-97(1991) (Pubitemid 121001225)
100. F. Lamballe, R. Klein and M. Barbacid: TrkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3. Cell 66, 967-979(1991) (Pubitemid 121001730)
101. K. C. Wang, J. A. Kim, R. Sivasankaran, R. Segal and Z. He: P75 interacts with the Nogo receptor as a coreceptor for Nogo, MAG and OMgp. Nature 420, 74-78(2002) (Pubitemid 35291442)
102. L. Dupuis, M. Pehar, P. Cassina, F. Rene, R. Castellanos, C. Rouaux, M. Gandelman, L. Dimou, M. E. Schwab, J. P. Loeffler, L. Barbeito and J. L. Gonzalez de Aguilar: Nogo receptor antagonizes p75NTR-dependent motor neuron death. Proc Natl Acad Sci U S A, 105(2), 740-5(2008) (Pubitemid 351171778)
103. S. Rabizadeh, J. Oh, L. T. Zhong, J. Yang, C. M. Bitler, L. L. Butcher and D. E. Bredesen: Induction of apoptosis by the low-affinity NGF receptor. Science 16, 345-348(1993) (Pubitemid 23281003)
104. J. M. Frade, A. Rodriguez-Tebar and Y. A. Barde: Induction of cell death by endogenous nerve growth factor through its p75 receptor. Nature 383, 166-168(1996) (Pubitemid 26303978)
105. P. Casaccia-Bonnefil, B. D. Carter, R. T. Dobrowsky and M. V. Chao: Death of oligodendrocytes mediated by the interaction of nerve growth factor with its receptor p75. Nature 383, 716-719(1996) (Pubitemid 26360647)
106. H. K. Teng, K. K. Teng, R. Lee, S. Wright, S. Tevar, R. D. Almeida, P. Kermani, R. Torkin, Z. Y. Chen, F. S. Lee, R. T. Kraemer, A. Nykjaer and B. L. Hempstead: ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin. J Neurosci 25, 5455-5463(2005) (Pubitemid 40770927)
107. A. Nykjaer, R. Lee, K. K. Teng, P. Jansen, P. Madsen, M. S. Nielsen, C. Jacobsen, M. Kliemannel, E. Schwarz, T. E. Willnow, B. L. Hempstead and C. M. Petersen: Sortilin is essential for proNGF-induced neuronal cell death. Nature, 427(6977), 843-8(2004) (Pubitemid 38297746)
108. P. Jansen, K. Giehl, J. R. Nyengaard, K. Teng, O. Lioubinski, S. S. Sjoegaard, T. Breiderhoff, M. Gotthardt, F. Lin, A. Eilers, C. M. Petersen, G. R. Lewin, B. L. Hempstead, T. E. Willnow and A. Nykjaer: Roles for the pro-neurotrophin receptor sortilin in neuronal development, aging and brain injury. Nat Neurosci, 10(11), 1449-57(2007) (Pubitemid 350014687)
109. K. C. Kanning, M. Hudson, P. S. Amieux, J. C. Wiley, M. Bothwell and L. C. Schecterson: Proteolytic processing of the p75 neurotrophin receptor and two homologs generates C-terminal fragments with signaling capability. J Neurosci, 23(13), 5425-36(2003) (Pubitemid 36807816)
110. J. C. Arevalo and S. H. Wu: Neurotrophin signaling: many exciting surprises! Cell Mol Life Sci, 63(13), 1523-37(2006) (Pubitemid 44156749)
111. J. M. Frade and Y. A. Barde: Genetic evidence for cell death mediated by nerve growth factor and the neurotrophin receptor p75 in the developing mouse retina and spinal cord. Development 126, 683-690(1999) (Pubitemid 29106175)
112. P. Podlesniy, A. Kichev, C. Pedraza, J. Saurat, M. Encinas, B. Perez, I. Ferrer and C. Espinet: Pro-NGF from Alzheimer's disease and normal human brain displays distinctive abilities to induce processing and nuclear translocation of intracellular domain of p75NTR and apoptosis. Am J Pathol, 169(1), 119-31(2006)
113. N. F. Schor: The p75 neurotrophin receptor in human development and disease. Prog Neurobiol, 77(3), 201-14(2005) (Pubitemid 41679399)
114. Y. Hashimoto, Y. Kaneko, E. Tsukamoto, H. Frankowski, K. Kouyama, Y. Kita, T. Niikura, S. Aiso, D. E. Bredesen, M. Matsuoka and I. Nishimoto: Molecular characterization of neurohybrid cell death induced by Alzheimer's amyloid-beta peptides via p75NTR/PLAIDD. J Neurochem, 90(3), 549-58(2004) (Pubitemid 38989385)
115. V. Della-Bianca, F. Rossi, U. Armato, I. Dal-Pra, C. Costantini, G. Perini, V. Politi and G. Della Valle: Neurotrophin p75 receptor is involved in neuronal damage by prion peptide-(106-126). J Biol Chem 276, 38929-38933(2001)
116. P. Schneider, J. L. Bodmer, M. Thome, K. Hofmann, N. Holler and J. Tschopp: Characterization of two receptors for TRAIL. FEBS Lett 416, 329-334(1997) (Pubitemid 27475391)
117. P. Schneider, M. Thome, K. Burns, J. L. Bodmer, K. Hofmann, T. Kataoka, N. Holler and J. Tschopp: TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity 7, 831-836(1997) (Pubitemid 28064896)
118. G. Pan, K. O'Rourke, A. M. Chinnaiyan, R. Gentz, R. Ebner, J. Ni and V. M. Dixit: The receptor for the cytotoxic ligand TRAIL. Science 276, 111-113(1997) (Pubitemid 27161256)
119. P. M. Chaudhary, M. Eby, A. Jasmin, A. Bookwalter, J. Murray and L. Hood: Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 7, 821-830(1997) (Pubitemid 28064895)
120. G. Pan, J. Ni, Y. F. Wei, G. Yu, R. Gentz and V. M. Dixit: An antagonist decoy receptor and a death domaincontaining receptor for TRAIL. Science 277, 815-818(1997) (Pubitemid 27366732)
121. J. P. Sheridan, S. A. Marsters, R. M. Pitti, A. Gurney, M. Skubatch, D. Baldwin, L. Ramakrishnan, C. L. Gray, K. Baker, W. I. Wood, A. D. Goddard, P. Godowski and A. Ashkenazi: Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science, 277(5327), 818-21(1997) (Pubitemid 27366733)
122. H. Walczak, R. E. Miller, K. Ariail, B. Gliniak, T. S. Griffith, M. Kubin, W. Chin, J. Jones, A. Woodward, T. Le, C. Smith
123. P. Smolak, R. G. Goodwin, C. T. Rauch, J. C. Schuh and D. H. Lynch: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med, 5(2), 157-63(1999) (Pubitemid 29068521)
124. J. Dorr, I. Bechmann, S. Waiczies, O. Aktas, H. Walczak, P. H. Krammer, R. Nitsch and F. Zipp: Lack of tumor necrosis factor-related apoptosis-inducing ligand but presence of its receptors in the human brain. J Neurosci, 22(4), RC209(2002)
125. S. Frank, U. Kohler, G. Schackert and H. K. Schackert: Expression of TRAIL and its receptors in human brain tumors. Biochem Biophys Res Commun 257, 454-459(1999) (Pubitemid 29303005)
126. K. Shah, G. Hsich and X. O. Breakefield: Neural precursor cells and their role in neuro-oncology. Dev Neurosci, 26, 118-130(2004) (Pubitemid 40867970)
127. C. J. Hawkins: TRAIL and malignant glioma. Vitam Horm 67, 427-452(2004) (Pubitemid 39753673)
128. J. M. Kuijlen, J. J. Mooij, I. Platteel, E. W. Hoving, W. T. van der Graaf, M. M. Span, H. Hollema and W. F. den Dunnen: TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme. J Neurooncol, 78(2), 161-71(2006) (Pubitemid 44339684)
129. S. Fulda, W. Wick, M. Weller and K. M. Debatin: Smac agonists sensitize for Apo2L/TRAIL-or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med, 8(8), 808-15(2002)
130. S. Hopkins-Donaldson, J. L. Bodmer, K. B. Bourloud, C. B. Brognara, J. Tschopp and N. Gross: Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factorrelated apoptosis-inducing ligand-induced apoptosis. Cancer Res 60, 4315-4319(2000) (Pubitemid 32103601)
131. J. P. Steinbach and M. Weller: Apoptosis in Gliomas: Molecular Mechanisms and Therapeutic Implications. J Neurooncol, 70(2), 247-256(2004)
132. M. Matysiak, A. Jurewicz, D. Jaskolski and K. Selmaj: TRAIL induces death of human oligodendrocytes isolated from adult brain. Brain 125, 2469-2480(2002) (Pubitemid 35303506)
133. B. Cannella, S. Gaupp, K. M. Omari and C. S. Raine: Multiple sclerosis: Death receptor expression and oligodendrocyte apoptosis in established lesions. J Neuroimmunol, 188(1-2), 128-37(2007) (Pubitemid 47095021)
134. F. Zipp and O. Aktas: The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci, 29(9), 518-27(2006) (Pubitemid 44291819)
135. O. Aktas, A. Smorodchenko, S. Brocke, C. Infante-Duarte, U. Schulze Topphoff, J. Vogt, T. Prozorovski, S. Meier, V. Osmanova, E. Pohl, I. Bechmann, R. Nitsch and F. Zipp: Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron, 46(3), 421-32(2005) (Pubitemid 40616886)
136. O. Aktas, S. Waiczies and F. Zipp: Neurodegeneration in autoimmune demyelination: recent mechanistic insights reveal novel therapeutic targets. J Neuroimmunol, 184(1-2), 17-26(2007) (Pubitemid 46365988)